CA2879427A1 - Method of diagnosis and treatment - Google Patents

Method of diagnosis and treatment Download PDF

Info

Publication number
CA2879427A1
CA2879427A1 CA2879427A CA2879427A CA2879427A1 CA 2879427 A1 CA2879427 A1 CA 2879427A1 CA 2879427 A CA2879427 A CA 2879427A CA 2879427 A CA2879427 A CA 2879427A CA 2879427 A1 CA2879427 A1 CA 2879427A1
Authority
CA
Canada
Prior art keywords
genes
tumour
irf7
metastatic
ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2879427A
Other languages
English (en)
French (fr)
Inventor
Belinda Sheree PARKER
Paul John HERTZOG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peter MacCallum Cancer Institute
Original Assignee
La Trobe University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49948115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2879427(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2012903104A external-priority patent/AU2012903104A0/en
Application filed by La Trobe University filed Critical La Trobe University
Publication of CA2879427A1 publication Critical patent/CA2879427A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/56—IFN-alpha
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7156—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2879427A 2012-07-20 2013-07-19 Method of diagnosis and treatment Abandoned CA2879427A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012903104 2012-07-20
AU2012903104A AU2012903104A0 (en) 2012-07-20 Method of diagnosis and treatment
PCT/AU2013/000801 WO2014012147A1 (en) 2012-07-20 2013-07-19 Method of diagnosis and treatment

Publications (1)

Publication Number Publication Date
CA2879427A1 true CA2879427A1 (en) 2014-01-23

Family

ID=49948115

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2879427A Abandoned CA2879427A1 (en) 2012-07-20 2013-07-19 Method of diagnosis and treatment

Country Status (7)

Country Link
US (1) US10441636B2 (enExample)
EP (1) EP2874647B1 (enExample)
JP (1) JP2015524397A (enExample)
CN (1) CN104703620A (enExample)
AU (3) AU2013293049A1 (enExample)
CA (1) CA2879427A1 (enExample)
WO (1) WO2014012147A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8834423B2 (en) 2009-10-23 2014-09-16 University of Pittsburgh—of the Commonwealth System of Higher Education Dissolvable microneedle arrays for transdermal delivery to human skin
TWI718086B (zh) * 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
CN103966334B (zh) * 2014-05-20 2015-09-23 李群 Csf2rb基因在前列腺癌骨转移中的应用
KR20190137957A (ko) * 2014-11-06 2019-12-11 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 암 치료 응용을 위한 미세바늘 어레이
WO2016149673A1 (en) 2015-03-18 2016-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bioactive components conjugated to substrates of microneedle arrays
CA2986114A1 (en) 2015-05-22 2016-12-01 La Trobe University Method of diagnosis of breast cancer
CN106319038B (zh) * 2015-07-02 2020-03-24 上海伯豪医学检验所有限公司 用于胃癌早期筛查的基因标志物及其应用
US20180268937A1 (en) * 2015-09-24 2018-09-20 Caris Science, Inc. Method, apparatus, and computer program product for analyzing biological data
WO2017066768A1 (en) 2015-10-16 2017-04-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Mullti-component biio-active drug delivery and controlled release to the skin by microneedle array devices
CN106701904B (zh) * 2015-11-17 2020-06-12 上海市东方医院 Acsl4基因和表达产物在胃癌诊断与治疗中的应用
US11230735B2 (en) 2015-12-24 2022-01-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for characterizing sepsis
US11744889B2 (en) 2016-01-05 2023-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education Skin microenvironment targeted delivery for promoting immune and other responses
CN108721603B (zh) * 2017-04-14 2020-11-13 中国医学科学院基础医学研究所 干扰素α-1a在制备用于治疗癌症的药物中的用途
WO2020232394A1 (en) 2019-05-16 2020-11-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Microneedle arrays with undercut features for cutaneous and non-cutaneous drug delivery
KR102854745B1 (ko) * 2020-04-23 2025-09-04 진크래프트 주식회사 R-point 조절 단백질 복합체를 유효성분으로 포함하는 폐암 치료용 약학적 조성물, 상기 복합체의 형성 여부를 이용한 폐암 치료제 스크리닝 방법 및 폐암 진단 방법
CN111863126B (zh) * 2020-05-28 2024-03-26 上海市生物医药技术研究院 构建结直肠肿瘤状态评估模型的方法及应用
CN114480608B (zh) * 2020-10-27 2024-09-06 细胞图谱有限公司 外周血样本分析方法和试剂盒

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US5753187A (en) 1996-06-14 1998-05-19 Stovall Life Science, Inc. Combinatorial chemistry cassette
GB9920906D0 (en) * 1999-09-03 1999-11-10 Glaxo Group Ltd Increased production of interferon-a
US7955800B2 (en) * 2002-06-25 2011-06-07 Advpharma Inc. Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients
US20080014579A1 (en) * 2003-02-11 2008-01-17 Affymetrix, Inc. Gene expression profiling in colon cancers
US20080003202A1 (en) 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides

Also Published As

Publication number Publication date
AU2020200253A1 (en) 2020-02-06
AU2013293049A1 (en) 2015-02-26
CN104703620A (zh) 2015-06-10
US10441636B2 (en) 2019-10-15
AU2018203670A1 (en) 2018-06-14
EP2874647A1 (en) 2015-05-27
WO2014012147A1 (en) 2014-01-23
JP2015524397A (ja) 2015-08-24
EP2874647A4 (en) 2016-04-13
US20150174205A1 (en) 2015-06-25
EP2874647B1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
EP2874647B1 (en) Method of diagnosis and treatment of metastatic cancer
US11873486B2 (en) Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
JP5589149B2 (ja) 癌に関与するポリヌクレオチド配列およびポリペプチド配列
US11243205B2 (en) Method of diagnosis of breast cancer
KR20080080525A (ko) 유전자 전사에 대한 ｆｇｆｒ３의 억제제의 효과
US12054787B2 (en) Compositions and methods comprising digital signatures to predict response and resistance to targeted therapy and immunotherapy
CN113260633A (zh) 用于癌症免疫疗法的诊断方法和组合物
WO2019178217A1 (en) Methods and compositions for treating, diagnosing, and prognosing cancer
WO2003008552A9 (en) Mll translocations specify a distinct gene expression profile, distinguishing a unique leukemia
CA2983004A1 (en) Methods for treating myeloproliferative disorders
KR102194746B1 (ko) Wnt 억제제와 연관된 마커
CA3057157A1 (en) Biomarkers for cancer therapeutics
WO2021162981A2 (en) Methods and compositions for identifying castration resistant neuroendocrine prostate cancer
US20250195644A1 (en) Compositions For and Methods of Preventing Metastases
JP5363695B2 (ja) 結腸癌に関するポリヌクレオチド
WO2006014903A2 (en) Compositions and methods of use for adam12 antagonists in treating disease
JP2008507261A (ja) 肺癌診断のための新規のヌクレオチド配列およびアミノ酸配列、ならびにそのアッセイおよび使用方法
JP2005505267A (ja) 癌において差次的に発現する膜貫通タンパク質
EP1749025A2 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of colon cancer
US20240247065A1 (en) Methods of treatment of cancer patients having altered setd2 biomarker with a pd-1 antagonist
HK40058894A (en) Diagnostic methods and compositions for cancer immunotherapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180618

FZDE Discontinued

Effective date: 20221122

FZDE Discontinued

Effective date: 20221122